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Abstract
Allogeneic hematopoietic cell transplantation (alloHCT) can induce long term remissions in 
chemosensitive relapsed follicular lymphoma (FL). The BMT CTN conducted a multicenter phase 
2 trial to examine the efficacy of alloHCT using reduced intensity conditioning (RIC) with 
rituximab (RTX) in multiply relapsed, chemosensitive FL. The primary endpoint was 2 year 
progression-free survival (PFS). The conditioning regimen consisted of fludarabine, 
cyclophosphamide and high-dose RTX (FCR) in which 3 of the 4 doses of RTX were administered 
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at a dose of 1 gm/m2. Graft vs host disease (GvHD) prophylaxis was with tacrolimus and 
methotrexate. Sixty five patients were enrolled and 62 were evaluable. Median age was 55 years 
(range, 29-74). This group was heavily pre-treated: 77% had received ≥ 3 prior regimens, 32% had 
received ≥ 5 prior regimens and 11% had received prior autologous HCT. Donors were HLA-
matched siblings (n=33) or HLA-matched unrelated adults (n=29). No graft failures occurred. The 
overall response rate after HCT was 94% with 90% in complete remission (CR), including 24 
patients not in CR before alloHCT. With a median follow-up of 47 months (range, 30-73), 3 year 
PFS and overall survival rates were 71% (95% confidence interval: 58%-81%) and 82% 
(70%-90%) respectively. Three year cumulative incidences of relapse/progression and non-relapse 
mortality were 13% and 16%, respectively. Two year cumulative incidences of grade 2-4 and grade 
3-4 acute GvHD were 27% and 10%, respectively and extensive chronic GvHD incidence was 
55%. Serum RTX concentrations peaked at day +28 and remained detectable as late as 1 year in 
59% of patients with available data. In conclusion, alloHCT with FCR conditioning confers high 
CR rates, a low incidence of relapse/progression and excellent survival probabilities in heavily 
pretreated FL patients.
 INTRODUCTION
Follicular lymphoma (FL) affects approximately 15,000 patients per year in the United 
States. The median age at diagnosis is 60 years with incidence increasing with age1. When 
treatment is indicated, RTX-based regimens are the standard of care and many achieve 
remission 2-4. The disease course is typically indolent and the median survival is 14-15 years 
from diagnosis. However, FL is incurable with standard therapy. Patients with poor risk 
features such as short remission duration after initial chemotherapy (<2-3 years) have a 
dramatically shorter expected survival 4. High dose chemotherapy with autologous HCT can 
confer long term remissions, especially if a patient is not heavily pretreated prior to HCT 5-7. 
However, allogeneic hematopoietic stem cell transplantation (alloHCT) is the only known 
curative modality for FL.
Earlier studies offering alloHCT with a myeloablative conditioning regimen demonstrated a 
significantly lower risk of relapse compared with autologous HCT but high treatment-related 
mortality (TRM) mitigated the benefit of this approach 8, 9. AlloHCT using a reduced 
intensity conditioning (RIC) regimen became widely utilized in FL patients. RIC affords a 
moderate degree of cytoreduction but also relies on potent immune-mediated graft-vs-
lymphoma effects to eradicate minimal residual disease. Results from several retrospective 
and prospective RIC alloHCT trials have yielded event-free survivals ranging from 
43%-75% and all demonstrate plateaus in relapse/progression5, 6, 10-15.
Previously, the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 
conducted a prospective “biologic assignment” trial in which chemosensitive FL patients 
beyond first response underwent either autologous HCT (autoHCT) or RIC alloHCT16. 
Patients with an available matched sibling donor were allocated to alloHCT and those 
without to autoHCT followed by maintenance therapy with RTX. Unfortunately, the trial 
closed prematurely due to slow accrual with only 30 patients enrolled; 22 patients underwent 
autoHCT and 8 patients underwent alloHCT. With a median follow-up of 36 months, the 
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PFS and OS for the autoHCT recipients were 63% and 73%, respectively and 86% vs 100% 
in the allogeneic group. Although the sample size was small from this study, results were 
encouraging as only 3 relapses were seen in the autologous arm vs 1 relapse in the 
allogeneic arm. The preparative regimen for alloHCT in that trial was modeled after the FCR 
(fludarabine, cyclophosphamide, RTX) conditioning regimen introduced by investigators at 
the M.D. Anderson Cancer Center. Using this regimen, the most encouraging results to date 
were reported in this single institution trial in 2012. The 11 year event-free and overall 
survival rates in 47 patients were 72% and 78%, respectively, with only 3 relapses 
reported.17. Based on this experience, the BMT CTN embarked on a prospective phase 2 
trial in the multicenter setting utilizing the same FCR regimen.
 METHODS
 Patients
Individuals 75 years of age and younger with histologically confirmed (grade I or II REAL 
or WHO grades 1, 2, or 3a FL in first or subsequent partial remission (PR) or second or 
subsequent complete remission (CR) were eligible for enrollment 18-20. If not in CR, 
response criteria compared to the most recent regimen required either 1) stable disease if all 
lymph node masses were ≤ 3 cm and unchanged (or smaller); or 2) chemotherapy sensitivity 
defined as reduction of all lymph node masses to ≤ 3 cm in axial diameter or, if larger than 3 
cm, a minimum of 50% reduction in estimated nodal diameters. Patients with documented 
evidence of transformation were excluded. There was no restriction on number of lines of 
prior therapy except that patients could not have received prior alloHCT. Prior autologous 
HCT was permitted.
Other eligibility criteria included adequate organ function defined as a cardiac ejection 
fraction of 45% or greater; total bilirubin less than twice the upper limit of normal (ULN); 
aspartate (AST) and alanine (ALT) serum transaminases less than thrice ULN; a creatinine 
clearance of at least 40mL/min; and diffusion capacity of carbon monoxide, forced 
expiratory volume in 1 minute, and forced vital capacity all more than 50% of normal after 
adjustment for hemoglobin. Patients were seronegative for human immunodeficiency virus 
(HIV) and could not have evidence of active hepatitis B (HBV) or hepatitis C (HCV) by 
serology and/or viremia. Patients with uncontrolled infections, defined as progressing on 
appropriate antimicrobial therapy, were ineligible. Patients with prior malignancy expect 
resected basal cell carcinoma or treated cervical carcinoma in situ or those women pregnant 
or breastfeeding were excluded.
Donor eligibility included either 1) fully matched (6/6 allele) related donors based on high 
resolution typing at HLA-DRβ1 and intermediate resolution typing at HLA-A and –B 
typing; or 2) fully matched (8/8 allele) unrelated donors based on high resolution typing at 
HLA-A, -B, -C, and -DRβ1. Donors met medical eligibility of the transplant center (related) 
or National Marrow Donor Program (NMDP). Related donors were excluded if they had 
evidence of infection with HIV, HBV, HCV or had prior malignancy other than treated basal 
cell or carcinoma in situ of the cervix. Identical twins were not permitted.
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 Study Design and Treatment
 Design—This multi-center, single-arm, phase II trial was designed to confirm the 
efficacy of a previously published RIC regimen followed by alloHCT 17. The protocol and 
informed consents were approved by the Protocol Review Committee and Data and Safety 
Monitoring Board, each independently appointed by the National Heart Lung and Blood 
Institute (NHLBI) and the Institutional Review Boards of all participating institutions. The 
study was led by the NHLBI Blood and Marrow Transplant Clinical Trials Network in 
collaboration with the Eastern Cooperative Oncology Group and the Southwest Oncology 
Group. All patients signed informed consents in accordance with the Declaration of 
Helsinki. The study is registered at http://www.clinicaltrials.gov as NCT00912223.
 Conditioning—All patients received pre-transplant conditioning with RTX (Genentech, 
San Francisco, USA) at 375mg/m2 on day −13 and at 1000mg/m2 on day −6, day +1, and 
day +8. Patients received fludarabine intravenously (IV) at 30mg/m2/day and 
cyclophosphamide IV 750mg/m2/day on day −5, −4, and −3. Peripheral blood progenitor 
cells (PBPC) were infused on day 0. All donor cells were mobilized with G-CSF per 
institutional or NMDP guidelines to obtain a minimum PBPC graft of 2.0 × 106 
CD34+cells/kg with a goal collection of at least 5.0 × 106 CD34+ cells/kg. If less than 1.0 × 
106 CD34+cells/kg were collected after three leukaphereses, the patient was managed at the 
discretion of the treating physician.
 Graft-versus-Host Disease (GVHD) Prophylaxis—Oral tacrolimus (target trough 5 
– 15 ng/mL) and IV methotrexate 5 mg/m2/day on days +1, +3, and +6 were administered 
for all patients receiving a related donor transplant. Unrelated donor (URD) recipients 
received an additional dose of methotrexate of 5 mg/m2 on day +11. No patients received 
anti-thymocyte globulin. Tacrolimus taper was to start at day +180 in the absence of GVHD 
and the rate of taper was determined by the treating physician.
 Supportive Care—All patients received antimicrobial prophylaxis and blood product 
support in concordance with the BMT CTN Manual of Procedures. Use of hematopoietic 
growth factors following HCT and immunizations were administered per institutional 
guidelines.
 Follow-up and Disease Response
Disease response was assessed based on standard criteria 20. Within 4 weeks prior to the 
initiation of the conditioning regimen, all patients had disease staging including a bone 
marrow biopsy and aspirate, quantitative polymerase chain reaction (PCR) for assessment of 
t(14;18) in the peripheral blood, and imaging. Imaging included computed tomography (CT) 
of the chest, abdomen, and pelvis and a CT of the neck if prior evidence of neck 
disease. 18F-FDG positron emission tomography (PET) was recommended only if patients 
had known FDG-avid disease previously. All patients were restaged at 3 months, 12 months, 
and 24 months following HCT. Restaging included the same studies as prior to HCT with 
the exception that bone marrow biopsy was only required if patients had prior marrow 
involvement and peripheral blood quantitative PCR was only necessary in those patients 
with documented prior t(14;18).
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Additional assessments following HCT included immune reconstitution studies by flow 
cytometry and quantitative immunoglobulin concentrations at 3 months, 6 months, and 1 
year; peripheral blood chimerism analysis at 4 weeks, 8 weeks, 3 months, 6 months, and 1 
year. Serum RTX concentrations were obtained in all patients prior to HCT as well as 4 
weeks, 3 months, 6 months, and 1 year after HCT. Toxicities were assessed using the 
National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 at 4 
weeks, 8 weeks, 3 months, 6 months, 1 year and 2 years after HCT. GVHD was monitored 
and assessed weekly from day 0 through 14 weeks post-HCT and then at 6 months, 1 year, 
and 2 years following transplantation. Acute GVHD and chronic GVHD were scored using 
consensus criteria 21, 22
 Quality of Life Measures
Health Related Quality of Life was measured utilizing the Functional Assessment of Cancer 
Therapy-Bone Marrow Transplant (FACT –BMT) self- report, transplant specific 
questionnaire and the Short Form-36 (SF-36), a patient reported survey of health status. The 
FACT-BMT survey consists of questions linked to four subscales: physical well-being, 
social/family well-being, emotional well-being and functional well-being. The FACT-BMT 
Total is the grand total of all items in the FACT-G and BMT modules and was used as the 
outcome measure in summarizing the FACT-BMT data23. Standardized effect sizes were 
computed for each subscale and for the total by comparing the 2-year measurement to the 
baseline. The SF-36 assessed the health QOL with eight components: physical functioning, 
role limitations-physical, body pain, general health, vitality, social functioning, role 
limitations-emotional and mental health24. These domains can be aggregated into the 
physical component summary and the mental component summary as weight sums of the 
domain scores. All assessments were conducted prior to the initiation of conditioning 
therapy and at 2 years post-HCT. The questionnaires were scored according to standard 
procedures.
 Statistical Analysis
All data were reviewed by an Endpoint Review Committee consisting of physicians on the 
protocol team or from the highest accruing centers. All study data for primary and secondary 
endpoints were reviewed and adjudicated in a blinded manner. The data cut-off was 
February 15, 2016. Using the historical 2-year PFS of 55% following autologous HCT, the 
study required enrollment of 65 patients to provide 80% power, with a two-sided α of 0.05, 
to reject the null hypothesis if the true PFS following the intervention was ≤73%.
The primary endpoint of the trial was 2-year PFS. Patients were considered to meet the 
primary endpoint if they died, experienced relapse/progression or received any therapy not 
specified in the protocol to prevent or treat relapse/progression, to induce a tumor response, 
or for mixed chimerism (i.e. donor lymphocyte infusion). The probability of PFS and overall 
survival (OS) were estimated by the Kaplan-Meier product limit estimator and the 
confidence interval calculated 25. The cumulative incidence of progression/relapse, acute 
GVHD, chronic GVHD and treatment related mortality (TRM) were determined using a 
competing risks analysis with death (for GVHD) or relapse/progression (for TRM) as the 
competing risk 26. Descriptive statistics were utilized to assess frequency and proportions of 
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patients obtaining CR/PR, primary and secondary graft failure, toxicities, infections, and 
immunologic reconstitution. Neutrophil and platelet recovery were assessed using the 
cumulative incidence function with death as a competing risk. Neutrophil recovery was 
determined as the first of 3 consecutive days with an absolute neutrophil count (ANC) >500/
μL. Platelet recovery was determined as the first of 3 consecutive days with platelet count 
>20,000/μL with no platelet transfusions in the prior 7 days. Primary graft failure was 
defined as donor peripheral blood T-cell chimerism <5% at day +30 after HCT. Secondary 
graft failure was defined as documented donor T-cell chimerism followed by loss of graft 
defined as <5% donor T-cells in a peripheral blood chimerism analysis. Correlation of RTX 
concentrations with development of acute GVHD, chronic GVHD and relapse were 
analyzed using a Cox regression model and time dependent covariates to assess the effect of 
RTX concentrations. Association between RTX concentrations and immune recovery were 
explored using correlation analysis. The statistical analyses were performed with SAS 
software, version 9.3 (SAS Institute). The cumulative incidence analyses were performed 
with the use of R software, version 2.15.1.
 Results
 Patient Characteristics
Sixty-five patients from 21 transplant centers were enrolled and transplanted between April 
2009 and November 2012. Three patients were deemed not evaluable due to consent 
withdrawal (n=1), not transplanted (n = 1), and not eligible due to transformed disease (n = 
1). Therefore, 62 patients were included in the primary analysis. Table 1 shows the 
characteristics of the patients and donors. Thirty-three (53%) received grafts from related 
and 29 (47%) from unrelated donors. The median age of all patients at the time of transplant 
was 55 (range, 29 – 74) years. The median time from diagnosis to alloHCT was 4.8 years 
(range, 1.0 - 23.8 years). All patients had pathologically confirmed follicular lymphoma 
without evidence of transformation [REAL 1, n = 8; REAL II, n = 6; WHO 1, n = 13; WHO 
2, n = 23; WHO 3a, n = 12] with most patients having WHO 2 or WHO 3a disease. The 
patients were generally heavily pre-treated with 32 (52%) receiving 4 or more prior 
treatment regimens for lymphoma and only 6 (10%) patients in a first partial remission; 7 
(11%) patients had previously received high dose chemotherapy and autologous HCT. 
Thirty-five (57%) recipients were CMV seropositive. The median follow-up of survivors 
was 47 (range, 30 – 73) months.
 Engraftment and Chimerism
Early neutrophil recovery was seen in all patients with a median time to neutrophil 
engraftment of 13 (range, 8 - 48) days and a day 30 cumulative incidence of neutrophil 
engraftment of 98% (94 – 100%). Three patients did not drop their ANC below 500/mm3. 
Grade 3 – 4 neutropenia occurred both early and late, with 21% of patients experiencing late 
neutropenia between 6 months and 1 year post-transplant, although no severe neutropenia 
beyond 1 year was reported and neutropenia completely resolved in all patients by 2 years 
post-HCT. By day 30, the median donor peripheral T-cell chimerism was 94% (range, 25 - 
100) and improved to 96% (range, 25 - 100) by day 100. This was similar for patients 
receiving related [day 30: 88% (20 – 100); day 100: 95% (25 – 100)] and unrelated [day 30: 
Laport et al. Page 6













95% (44 – 100); day 100: 96 (69 – 100)] donor grafts. No patients experienced primary or 
secondary graft failure.
 Survival
At a median follow-up of 47 months, the primary endpoint of 2 year PFS was 73% (95% 
confidence interval [CI]: 60 – 82%), Figure 1. Follow-up beyond 2 years was available for 
52 patients and two patients died beyond 2 years after HCT. Three patients relapsed beyond 
2 years after HCT and the estimated 3-year PFS is 71% (95% CI: 58 – 81%). The 2 year and 
3 year OS were 84% (95% CI: 72 – 91%) and 82% (95% CI: 70 – 90%), Figure 1. When 
analyzing survival by donor type, the MRD recipients showed a superior 2-year OS 
compared to the URD recipients, 94% (95% CI: 78%, 98%) vs 72% (95% CI: 52%, 85%), 
p=.02, although the difference in 2-year PFS was not significant, 76% (95% CI: 57%, 87%) 
vs 69% (95% CI: 49% vs 83%), p= 0.55.
 Response to Transplantation
Disease status at the time of transplant is shown in Table 1. At baseline, 30 patients had a 
PET scan to determine disease status with 17 assessed as CR and 13 as not in CR. Among 
24 patients not in CR at the time of transplant, only 6 did not obtain a CR as the best 
response post-transplant. Two of these patients were not evaluated due to death from 
infection on day 74 and death from acute GVHD on day 111. Two patients remained in PR 
and 2 patients experienced disease progression early both at 3 months after HCT. Overall, 
the 3-year cumulative incidence of relapse/progression was 13% (95% CI: 6 – 23%), Figure 
2. Among patients transplanted in CR, the 2-year cumulative incidence of relapse/
progression was lower compared to the patients transplanted in PR although this was not 
statistically significant, 6% (95% CI: 1% vs 18%) vs 21% (95% CI: 9%, 38%) , p=0.08, 
respectively. However, the patients in CR at time of HCT showed a significantly superior 2-
year PFS and OS compared to the PR patients. The PFS for the CR patients and PR patients 
were 88% (95% CI: 70%, 95%) vs 57% (95% CI: 37%, 73%), p=.01, respectively and for 
OS, 94% (95% CI: 77%, 98%) vs 75% (95% CI: 55%, 87%), p=.04, respectively.
 Graft-versus-Host Disease
Acute GVHD occurred in 17 patients by day 100. No patients developed grade IV acute 
GVHD and only 6 patients developed grade III acute GVHD. The cumulative incidence of 
grade II – IV acute GVHD at day 100 was 27% (95% CI: 16 – 39%). Grade II-IV acute 
GVHD occurred in 18% (95% CI: 7 – 33%) of patients receiving MRD and 38% (21 – 55%) 
for MUD recipients; however, grade III/IV acute GVHD was similar [MRD: 9% (2 – 22%); 
MUD: 10% (3 – 25%)]. Chronic GVHD occurred in 37 patients, 35 of whom had extensive 
chronic GVHD. Chronic GVHD severity was mild in 7 (3 MRD, 4 URD) patients, moderate 
in 23 (12 MRD, 11 URD) patients, and severe in 7 (3 MRD, 4 MUD) patients. The 
cumulative incidence of any cGVHD at 2 years was 61% (95% CI: 48 – 74%). When 
analyzed by donor, the cumulative incidences of cGVHD for MRD recipients was 55% 
(95%CI: 36.0%, 70.4%) and 66% (95%CI: 44.4%, 80.2%) for URD recipients.
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Following HCT, 50 patients experienced at least one grade 3 – 5 toxicity during the first 2 
years. The most common toxicity was grade 3 – 4 neutropenia, occurring in 77% of patients. 
Other toxicities occurring in more than 10% of patients during the first two years included 
abnormal liver tests (n = 13) including grade 3 – 4 alanine aminotransferase (ALT) 
elevations in 7 patients and events of grade 3 – 4 hypoxia in 9 patients including 4 with 
pneumonitis developing beyond 2 months after alloHCT. Three patients developed 
unexpected, grade 3 – 5 adverse events including one patient with appendicitis at day +181 
and two patients who developed deep venous thrombosis at day +28 and day +51, 
respectively. Overall, the 3-year TRM was 16% (95% CI: 8 – 27%, Figure 2). Ten patients 
died by two years after alloHCT due to the following causes: relapse (n =1), GVHD (acute, 
n=3; chronic, n = 3), infection (n=2), and one patient who died unexpectedly at home in 
whom the cause was not determined. Beyond 2 years, two additional patients have died due 
to infection at 34 months (n=1) and interstitial pulmonary fibrosis at 42 months (n=1). 
Donor type significantly affected TRM as the incidence of TRM at 2 years among the MRD 
vs URD recipients were 3% (95% CI: 0.2%- 15%) vs 28% (95% CI: 13% - 45%). Notably, 
for the 6 patients with GVHD as the COD, all 3 patients with aGVHD and 2 of the patients 
with cGVHD were recipients of URD transplants.
 Immune Recovery
Quantitative immunoglobulin levels and peripheral blood flow cytometry for lymphocyte 
subset analyses were obtained at baseline, day 100, day 180, and 1 year from transplant. At 
baseline, patients had an absence of CD19+ and CD20+ cells [CD19+, n = 53: median 0 
cells/μL (range, 0 – 300); CD20+, n = 37: median 0 cells/μL (range, 0 – 270)] and an 
associated mild hypogammaglobulinemia [IgG, n = 60: median 565 mg/dL (range 126 – 
1470); IgA, n = 60: median 92 mg/dL (range, 7 – 450); IgM, n = 60: median 25 mg/dL 
(range, 4 – 111). Notably, this did not improve over time with continued near absence of 
CD19+ and CD20+ cells at 1 year [CD19+, n = 45: median 15 cells/μL (range, 0 – 400); 
CD20+, n = 23: median 0 cells/μL (range, 0 – 400)]. This translated into long-term mild 
hypogammaglobulinemia with a median IgG level of 431 mg/dL (range, 79 – 1430; n = 53) 
at 1 year after transplant.
T-cell subsets of CD4 and CD8 were lowest at baseline [CD4, n = 53: median 250 cells/μL 
(range, 29 – 1350) and day 100 [CD8, n = 57: median 213 cells/μL (range, 36 – 2117)], 
respectively. However, by day 180, the CD4 count (n = 50) had dramatically improved to a 
median 317 cells/μL (range, 10 – 782). Similarly, the CD8 count (n = 50) improved [median 
262 cells/μL (range, 24 – 1698)].
 Impact of High Dose RTX on Outcomes
Per protocol, all patients received the first 3 doses of RTX (day −13, day −6, day +1) and 
only 2 patients missed the fourth dose of RTX on day +8. Serum RTX concentrations were 
collected at baseline (n=57), day +28 (n=56), day +100 (n=55), day +180 (n=53), and day 
+365 (n=44) for a compliance rate of 92%, 90%, 90%, 90%, and 80% at the assigned time 
points. At baseline, the median RTX concentration was 42,100 ng/mL (range, <500 – 70,200 
ng/mL) with 6 patients having undetectable concentrations of RTX (Figure 3). As expected, 
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RTX concentrations peaked at day +28 [median 341,000 ng/mL (range, <500 – 670,000 ng/
mL)] with only 1 patient having undetectable concentrations. By day +365, 28 (64%) 
patients still had detectable RTX concentrations at a median level of 920 ng/mL (range, 
<500 – 122,000 ng/mL). RTX concentrations did not differ based on donor type (data not 
shown). For patients in CR at the time of transplant, the median RTX concentration at 
baseline was 53,800 ng/mL (range <500 – 166,000 ng/mL) compared to only 29,000 ng/mL 
(<500 – 110,000 ng/mL) for non-CR patients; however, by day +28 and all subsequent 
assessments, the median RTX concentrations were nearly identical [day 28: CR = 345,000 
ng/mL (range, 73,400 – 670,000); non-CR = 341,000 (range, <500 – 564,000)] (data not 
shown for other assessments). When analyzing median RTX concentrations using landmark 
analysis, OS was significantly higher among patients who had a higher median serum 
concentration vs a lower serum concentration at day +28 with a 2 year OS of 96% (95% CI: 
77%, 100%) vs 67%, (95% CI: 47% vs 82%), p=.01, respectively (Figure 4a). In univariate 
analysis treating RTX as a continuous variable, patients who developed Grade III/IV acute 
GVHD (n = 6) and patients who died (n =10) were more likely to have a lower day +28 RTX 
concentration [aGVHD grade III/IV yes, median: 272,500 ng/mL vs no: 351,000 ng/mL, p = 
0.03; death yes, median: 253,093 ng/mL vs no: 353,000 ng/mL, p = 0.009)]. These results 
were consistent when categorizing RTX as high or low based on the median value of the 
cohort at day +28 (Figure 4b). There was no impact of RTX concentrations on the 
development of chronic GVHD or on relapse or progression of lymphoma (data not shown).
 Quality of Life Measures
The results from the SF-36 instrument showed no statistically significant difference in SF-36 
score between the baseline and 2 year timepoints except that the raw SF-36 ‘health 
transition’ item did show improvement from a mean score of 3 at baseline to 2 at 2-years 
(with 2 indicating that general health somewhat better now than one year ago, 3 indicating 
that general health about the same as one year ago). The FACT-BMT scores at baseline and 
at 2 years did not show a significant difference at years (data not shown)
 DISCUSSION
We report the results of the largest prospective series of FL patients who underwent RIC 
alloHCT using a uniform conditioning regimen with a T-cell replete graft. Sixty five 
patients, of which 62 were evaluable, received the FCR regimen incorporating high dose 
RTX. The 2 year PFS and OS rates of 74% and 84% were notable considering that this was a 
heavily pre-treated patient population. Nearly 80% of the patients had received 3 prior 
regimens with one third of the patients having received 5 prior regimens and 11% receiving 
a prior autologous HCT. More importantly, these excellent outcomes were maintained with 
longer follow-up. This was a well-tolerated regimen that can be administered in the 
outpatient setting. Our multi-center results are similar to the outcomes from the M.D. 
Anderson group who reported an 11 year PFS and OS of 72% and 78% in 47 patients who 
underwent RIC alloHCT (all but one from a related donor) with the same FCR regimen 14. 
Several prospective trials of FL patients undergoing RIC alloHCT, also using fludarabine-
based, regimens show median disease free survivals or EFS ranging from 43% −75% and 
OS ranging from 52% −81%5, 6, 10-15. As with our study, most of these prior studies also 
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included patients who had relapsed after a prior autologous HCT. In all studies, 
chemosensitivity at the time of HCT was the most consistent predictor of outcome. All of 
these trials also demonstrated plateaus in the relapse curves which were strongly suggestive 
of cure.
The low relapse incidence of 13% in this study was notable and partly attributed to the graft 
vs lymphoma effect mediated by donor T cells and to the lack of potential graft 
contamination of tumor cells in autologous grafts. Another possible contributor to the low 
relapse rate was the high dose of RTX administered. Patients received a total of 3.375 
gms/m2. Prior reports found an association between dose and serum RTX concentration as 
well as an association between serum RTX concentration and anti-tumor response in B-cell 
lymphoma27, 28. The serum half-life of RTX increases with subsequent infusions due to the 
elimination of circulating CD20+ B cells which clear serum antibody with the initial RTX 
infusions. Antibody clearance is also reduced due to saturation or reduction of involved 
nodal sites. In the current study, pharmacokinetic analyses revealed high serum 
concentrations at day +28 in the majority of patients for whom data were available, with 23 
patients showing detectable concentrations up to 1 year post HCT. When analyzing median 
RTX concentrations using landmark analysis, OS was significantly higher among patients 
who had a higher (>median) serum concentration vs a lower serum concentration at day +28 
(Kaplan-Meier estimator 96% vs 67%, respectively, p=.01). The improved OS associated 
with a higher day+28 RTX concentration could be attributed to the significantly lower risk 
of grade 3-4 acute GVHD seen in this specific subgroup. Acute and chronic GVHD were the 
leading causes of death in this study, and predominated in recipients of URD contributing to 
the higher TRM following URD transplant. Therefore, further improvement in outcomes 
may be achieved with efforts, such as the use of ATG, to decrease GVHD29.
Other direct effects of the high dose RTX were hypogammaglobulinemia and late 
neutropenia with the neutropenia resolving in all patients by 2 year post-HCT. We did not 
observe an increase in infection related deaths despite the observed neutropenia. T cell 
subsets, CD4+ and CD8+, remained within normal range throughout the transplant course. 
In contrast, peripheral blood B lymphocyte recovery was considerably impaired. At the start 
of HCT, CD19 and CD20+ subsets were undetectable which was attributed to prior RTX 
administration in all patients. However, at 1 year post HCT, CD19+ B cells showed minimal 
recovery while CD20+ B cells remained undetectable. Despite the impaired B cell immune 
reconstitution, an excess of opportunistic infections was not seen.
With the prolonged B cell depletion in the current study, we had originally hypothesized that 
acute or chronic GVHD might be reduced as recent data have implicated B cells in the 
pathogenesis of acute and chronic GVHD. B cell depletion therapy with RTX has reported 
efficacy in both the prevention and treatment of chronic GVHD, including steroid-refractory 
chronic GVHD30-33. We observed a correlation with RTX concentration at day +28 with a 
significantly lower incidence of grade 3 and no grade 4 acute GVHD in patients who had a 
high RTX concentration compared to patients who had lower concentration. However, the 
incidence of chronic GVHD was not impacted as we observed an incidence comparable to 
those reported in other studies with RIC allogeneic HCT in similarly aged patients. The lack 
of impact of RTX on the incidence of chronic GVHD may be explained by the complex 
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pathophysiology of chronic GVHD which requires a coordinated response from both B and 
T lymphocytes. Direct comparison of chronic GVHD incidences between different studies is 
also challenging due to the heterogeneity among chronic GVHD criteria and grading in the 
literature. Additionally, despite our observed incidence of chronic GVHD in 55% of 
patients, their self-reported QOL was unchanged from prior to HCT compared to 2 years 
after HCT.
An increasing body of data confirms the efficacy of non-myeloablative or RIC alloHCT 
leading to less enthusiasm for myeloablative regimens in this patient population. Two large 
registry studies from the Center for International Blood and Marrow Transplant Research 
(CIBMTR) and the European Group for Blood and Marrow Transplantation (EBMT) 
directly compared the outcomes of FL patients who underwent alloHCT either with a RIC or 
myeloablative regimen. The CIBMTR analyses reported that both PFS and OS were similar 
regardless of intensity of conditioning regimen although progression was significantly 
higher in the RIC group and TRM higher in the myeloablative group34. In contrast, in the 
EBMT study, the RIC recipients had improved PFS and OS compared to the ablative 
regimens with no difference in relapse rates between the two groups35. Both studies 
demonstrated that chemosensitivity rather than conditioning intensity was the most reliable 
predictor of outcome.
For FL patients with relapsed/refractory disease, autologous HCT (autoHCT) represents one 
of numerous other therapeutic options. In our study, 7 patients had previously received 
autologous HCT. While there has only been one prospective trial comparing autoHCT with 
RIC alloHCT for relapsed FL patients, this study closed prematurely due to poor accrual16. 
Retrospective and prospective studies with autologous HCT have yielded 5 year PFS ranging 
from 40%-60%6, 7, 15, 36, 37. Retrospective comparisons of autologous and allogeneic HCT 
for relapsed/refractory FL include a report from the National Comprehensive Cancer 
Network (NCCN) comparing the outcomes of 135 FL patients who received an autologous 
HCT to 49 patients who underwent either myeloablative or RIC allogeneic HCT5. Patients 
receiving alloHCT had lower relapse/progression than autoHCT recipients (16% vs 32%, 
p=0.03) but OS was improved in the autoHCT recipients (87% vs 61%, p <0.009). This 
disparity was ascribed to the difference in TRM between the groups (autoHCT 3% vs 
alloHCT 42%, p<0.0001). However, the alloHCT group had a higher proportion of patients 
with resistant disease. Multivariate analyses for the autologous cohort identified age > 60 
years old and having > 3 prior regimens as adverse factors for survival which is consistent 
with other reports7,38. The EBMT published a retrospective analyses comparing autologous 
HCT (n=726) to RIC alloHCT for relapsed FL 15. Similar to the NCCN report, relapse/
progression was higher following autoHCT (RR 3.1, p<0.001) and 1 year TRM was higher 
following alloHCT (RR 4.0, p<0.001); however, OS was similar between the two groups. 
Interestingly, while the median time to relapse was 13 months (range .6 -107 months) 
following autoHCT and 5.4 months (range 0.1 -76 months) after alloHCT, the alloHCT 
group demonstrated a plateau in relapse/progression at 24 months. There was no plateau 
following autoHCT.
In summary, this trial shows that RIC alloHCT using the FCR regimen in a multicenter 
setting yields high response rates with durable long term remissions for patients with 
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relapsed, chemosensitive FL. Numerous therapeutic options are available to FL patients but 
alloHCT remains the only curative strategy; these data suggest that it can be offered with 
acceptable safety to patients who fail other therapies. The optimal timing of alloHCT versus 
other FL therapies still remains to be determined.
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• AlloHCT with high dose RTX/Flu/Cy provides excellent PFS for high 
risk FL
• RTX remains detectable at 1 year from HCT in more than 50% of 
patients
• Timing of AlloHCT to optimize outcomes requires further study
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Progression-free (solid line) and overall survival (dashed line).
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Cumulative incidences of relapse/progression (solid line) and non-relapse mortality (dashed 
line)
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Serum RTX concentrations over time
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Acute grade 3-4 GVHD incidence by day +28 serum Rituxan level (high vs low)
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Overall survival by day +28 serum Rituxan level (high vs low)
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Table 1
Baseline characteristics of evaluable patients at the time of transplantation
Variable Frequency (%)
Gender, male 39 (63%)
Ethnicity
    Not Hispanic/Latino 58 (64%)
    Hispanic 4 (6%)
Karnofsky performance status
    100% 29 (47%)
    90% 28 (45%)




> 3 15 (24%)
Disease status
    Second or subsequent CR2 32 (52%)
    PR 1 6 (10%)
    Greater than/equal to PR2 16 (26%)
    Stable disease 2 (1%)
Number of Prior Chemotherapy Regimens
    2 14 (23%)
    3 16 (26%)
    4 12 (19%)
    ≥ 5 20 (32%)
Donor Type (HLA match)
    Matched Related (6/6 allele) 33 (53%)
    Matched Unrelated (8/8 allele) 29 (47%)
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